Effect of anti-CTGF human recombinant monoclonal antibody pamrevlumab on resectability and resection rate when combined with gemcitabine/nab-paclitaxel in phase 1/2 clinical study for the treatment of locally advanced pancreatic cancer patients. Article

Full Text via DOI: 10.1200/JCO.2018.36.15_suppl.4016 Web of Science: 000442916001593
Industry Collaboration

Cited authors

  • Picozzi, Vincent J.; Pishvaian, Michael J.; Mody, Kabir; Winter, Jordan Michael; Glaspy, John A.; Larson, Tim; Matrana, Marc Ryan; Saikali, Khalil; Carney, Mairead; Porter, Seth; Yu, Peony; Kouchakj, Elias; Carrier, Ewa

Publication date

  • 2018

Published in

International Standard Serial Number (ISSN)

  • 0732-183X


  • 36


  • 15